Paxlovid is an antiviral combination therapy that can reduce the risk of COVID-19 causing severe illness, hospitalization and ...

Nirmatrelvir is a protease inhibitor that stops the SARS-CoV-2 virus from replicating while ritonavir boosts the activity of nirmatrelvir. It is given in a five-day course with three pills taken twice ...

FDA researchers estimated, based on Covid rates in January, that Paxlovid could "lead to 1,500 lives saved and 13,000 hospitalizations averted each week" in the U.S.

Paxlovid is the most commonly prescribed at home treatment for COVID-19 in the U.S. It is approved to treat COVID in adults who are at risk of severe complications from the illness.

The findings are described in a paper to be published June 7 in JAMA Internal Medicine. Paxlovid is a highly effective antiviral agent licensed for treatment of acute COVID-19.

Paxlovid made no significant improvement to long COVID symptoms, including fatigue, brain fog and body aches. The finding “does not rule out” Paxlovid as a therapy, the researchers wrote.

Dr. Astha Muttreja, a physician at the Stony Brook Medicine's post-COVID Clinic in Lake Grove, said there had been “cautious optimism” that Paxlovid would be a potential treatment method for ...

Researchers have described the optimal timing for COVID-19 patients to take the antiviral, Paxlovid, to get the most benefit from the treatment, according to a study published April 16 in eLife.

Pfizer won't say. A Harvard study last year estimated the cost of producing generic Paxlovid at about $15 per treatment course, including manufacturing expenses, a 10% profit markup, and 27% in taxes.

Most people who take Paxlovid for the treatment of COVID do not get rebound COVID, but up to 20% of patients do. That doesn't mean that the drug isn't doing its job.

As soon as doctors determined on Thursday that President Biden had Covid-19, the White House doctor put him on the antiviral Paxlovid. Considered a game-changer when it was authorized in December ...

Paxlovid isn't the only antiviral medication for COVID-19. Merck’s Lagevrio is another available pill, though it's proven to be less popular in the U.S. than Paxlovid.